ERBB2 and cancer: Through binding to subdomain IV of the extracellular domain of overexpressed human epidermal growth factor receptor-2 (HER-2) receptors, trastuzumab blocks the receptor and inhibits excessive proliferation of HER-2-positive cancer cells.